Pharma

Your Article Summary

See Latest Articles

Update on FDA Registration of Actemra, a Humanized Anti-Human IL-6 Receptor Monoclonal Antibody for Rheumatoid Arthritis
Chugai Pharmaceutical Co., 08/03/09

Chugai Pharmaceutical Co., Ltd. and F. Hoffmann–La Roche Ltd. announced that FDA has accepted the complete response resubmission that Roche made to the U.S. Food and Drug Administration (FDA) for the Biologics License Application (BLA) for Actemra the humanized anti–human IL–6 (interleukin–6) receptor monoclonal antibody, following the receipt of the Complete Response Letter in September 2008.

Today in Regulatory Issues...keeping you current

Receive free subspecialty "5-minute updates" via email

Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease
Shire, 11/30/09

Tricare contracts may be re-bid after losing plans protest
American Medical News , 11/25/09

GSK Regulatory Update: Avodart
GlaxoSmithKline, 11/24/09

 See all of Regulatory Issues

Today in Research & Development...keeping you current

Receive free subspecialty "5-minute updates" via email

Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease
Shire, 11/30/09

Novartis inaugurates large-scale US based cell-culture influenza vaccine manufacturing facility
Novartis, 11/25/09

Bayer CropScience signs Agreement with GVK Biosciences on early-stage research projects
BayNews International, 11/25/09

 See all of Research & Development